RIGHT Choice最终结果:瑞波西利联合内分泌治疗对比联合化疗用于临床侵袭性激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌绝经前女性
RIGHT Choice是一项开放标签、多中心、随机II期试验,纳入222例临床侵袭性HR+/HER2-晚期乳腺癌绝经前/围绝经期女性,1:1随机接受一线瑞波西利联合内分泌治疗或研究者选择的联合化疗。瑞波西利组中位无进展生存期21.8个月,化疗组12.8个月(HR 0.61,95%CI 0.43-0.87,P=0.003);两组缓解率相似,瑞波西利组症状性不良事件发生率更低。
要点
- 瑞波西利联合内分泌治疗较联合化疗显著改善临床侵袭性HR+/HER2-晚期乳腺癌绝经前女性的无进展生存期。
- 瑞波西利组中位无进展生存期21.8个月,化疗组12.8个月,HR 0.61(95%CI 0.43-0.87),P=0.003。
- 两组总体缓解率分别为66.1%和61.8%,瑞波西利组症状性不良事件发生率更低。
核心结论
- 在一线治疗临床侵袭性HR+/HER2-晚期乳腺癌患者中,瑞波西利联合内分泌治疗较联合化疗显著改善无进展生存期,缓解率相似,耐受性更好。
研究设计与样本
- 开放标签、多中心、随机II期试验,纳入绝经前/围绝经期临床侵袭性HR+/HER2-晚期乳腺癌女性。
- 222例患者1:1随机分配至瑞波西利(600 mg每日一次,服3周停1周)联合来曲唑/阿那曲唑及戈舍瑞林组(n=112)或研究者选择的联合化疗组(n=110)。
- 主要终点为无进展生存期。
主要发现
- 150例(67.6%)有症状性内脏转移,41例(18.5%)研究者判断为快速疾病进展,31例(14.0%)有症状性非内脏病变,106例(47.7%)研究者评估为内脏危象。
- 中位随访时间37.0个月。
- 数据截止时,瑞波西利组31.3%、化疗组15.5%的患者完成研究治疗并转入试验后获取。
- 瑞波西利组中位无进展生存期21.8个月(95%CI 17.4-26.7),化疗组12.8个月(95%CI 10.1-18.4),HR 0.61(95%CI 0.43-0.87),P=0.003。
- 瑞波西利组与化疗组总体缓解率分别为66.1%和61.8%,中位缓解时间分别为4.9个月和3.2个月(HR 0.76,95%CI 0.55-1.06)。
临床怎么用
- 作者结论认为,对临床侵袭性HR+/HER2-晚期乳腺癌患者,一线瑞波西利联合内分泌治疗较联合化疗显著改善无进展生存期,缓解率相似,耐受性更好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A head-to-head comparison of efficacy between a cyclin-dependent kinase 4/6 inhibitor plus endocrine therapy (ET) versus combination chemotherapy (CT) has never been reported in patients with clinically aggressive hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). METHODS: In this open-label, multicenter, randomized phase II trial, pre/perimenopausal women with clinically aggressive HR+/HER2- ABC were randomly assigned 1:1 to first-line ribociclib (600 mg once daily; 3 weeks on, 1 week off) plus letrozole/anastrozole and goserelin or investigator's choice of combination CT (docetaxel plus capecitabine, paclitaxel plus gemcitabine, or capecitabine plus vinorelbine). The primary end point was progression-free survival (PFS). RESULTS: Among 222 patients randomly assigned to ribociclib plus ET (n = 112) or combination CT (n = 110), 150 (67.6%) had symptomatic visceral metastases, 41 (18.5%) had rapid disease progression per investigator's judgment, and 31 (14.0%) had symptomatic nonvisceral disease. Overall, 106 (47.7%) patients had investigator-assessed visceral crisis. The median follow-up time was 37.0 months. At data cutoff, 31.3% (ribociclib arm) and 15.5% (CT arm) of patients had completed study treatment and transitioned to post-trial access. The median PFS was 21.8 months (ribociclib plus ET; [95% CI, 17.4 to 26.7]) and 12.8 months (combination CT; [95% CI, 10.1 to 18.4); hazard ratio, 0.61 [95% CI, 0.43 to 0.87]; P = .003. The overall response rates and the median time to response in the ribociclib versus CT arms, respectively, were 66.1% and 61.8% and 4.9 months and 3.2 months (hazard ratio, 0.76 [95% CI, 0.55 to 1.06]). Lower rates of symptomatic adverse events were observed in the ribociclib versus CT arm. CONCLUSION: First-line ribociclib plus ET showed a significant PFS benefit, similar response rates, and better tolerability over combination CT in patients with clinically aggressive HR+/HER2- ABC.
引用
- Lu YS, Mahidin EIBM, Azim H, et al. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. J Clin Oncol. 2024. PMID: 38771995. doi:10.1200/JCO.24.00144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。